Participants
HR+ / HER2-
METASTATIC BREAST CANCER, METASTATIC DISEASE
Eligible patients have histologically or cytologically proven diagnosis of HR+ / HER2- locally advanced or metastatic breast cancer and are either candidates to receive palbociclib in combination with aromatase inhibitor or candidates to receive palbociclib in combination with fulvestrant for their locally advanced or metastatic disease. All anticancer treatments used in this study are approved drugs and therapy is in accordance to national treatment guidelines [There is no blinding process used in the study.For inclusion and exclusion criteria, please refer to Table PreCyclePatients are stratified according to their eligibility for receiving palbociclib with endocrine therapy (AI or fulvestrant) as first or later lines.The study includes a variety of different centers and clinical settings in Germany (university, community hospitals, private practice). More information including participating sites can be found at 